MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia

Leukemia Research

Volumn 37, Issue 10, 2013, Pages 1315-1321

  Akbari Moqadam, F ^a   Lange Turenhout, E A M ^a   Aries I M ^a   Pieters, R ^a   den Boer, M L ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Leukemia; MiR 100; MiR 125b; MiR 99a; MiRNA; Vincristine resistance

Indexed keywords

LENTIVIRUS VECTOR; MICRORNA; MICRORNA 100; MICRORNA 125B; MICRORNA 99A; TRANSCRIPTION FACTOR ETV6; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER RESISTANCE; CELL VIABILITY; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DNTT GENE; DOWN REGULATION; DRUG CYTOTOXICITY; EMBRYO; ETV6 GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; KIF5B GENE; MALAT1 GENE; NUCKS1 GENE; PNO1 GENE; PRIORITY JOURNAL; PRPS2 GENE; RPL23A GENE; RPL38 GENE; RPS11 GENE; RUNX1 GENE; SET GENE; SNRPE GENE;

LEUKEMIA; MIR-100; MIR-125B; MIR-99A; MIRNA; VINCRISTINE RESISTANCE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION REGULATION, LEUKEMIC; GENE ORDER; HUMANS; MICRORNAS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; VINCRISTINE;

EID: 84883558416     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.06.027     Document Type: Article

References (40)

1. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19(1):92-105.
2. Lytle J.R., Yario T.A., Steitz J.A. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc Natl Acad Sci U S A 2007, 104(23):9667-9672.
3. Wightman B., Burglin T.R., Gatto J., Arasu P., Ruvkun G. Negative regulatory sequences in the lin-14 3'-untranslated region are necessary to generate a temporal switch during Caenorhabditis elegans development. Genes Dev 1991, 5(10):1813-1824.
4. Lal A., Navarro F., Maher C.A., Maliszewski L.E., Yan N., O'Day E., et al. miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to seedless 3'UTR microRNA recognition elements. Mol Cell 2009, 35(5):610-625.
5. Lerner M., Lundgren J., Akhoondi S., Jahn A., Ng H.F., Akbari Moqadam F., et al. miRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle 2011, 10(13):2172-2183.
6. Ebert P.J., Jiang S., Xie J., Li Q.J., Davis M.M. An endogenous positively selecting peptide enhances mature T cell responses and becomes an autoantigen in the absence of microRNA miR-181a. Nat Immunol 2009, 10(11):1162-1169.
7. Ventura A., Young A.G., Winslow M.M., Lintault L., Meissner A., Erkeland S.J., et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008, 132(5):875-886.
8. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005, 102(39):13944-13949.
9. Curtale G., Citarella F., Carissimi C., Goldoni M., Carucci N., Fulci V., et al. An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes. Blood 2010, 115(2):265-273.
10. Schotte D., De Menezes R.X., Akbari Moqadam F., Khankahdani L.M., Lange-Turenhout E., Chen C. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica 2011, 96(5):703-711.
11. Feng D.D., Zhang H., Zhang P., Zheng Y.S., Zhang X.J., Han B.W., et al. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukemia. J Cell Mol Med 2011, 15(10):2164-2175.
12. Zhu Y.D., Wang L., Sun C., Fan L., Zhu D.X., Fang C., et al. Distinctive microRNA signature is associated with the diagnosis and prognosis of acute leukemia. Med Oncol 2012, 29(4):2323-2331.
13. Kotani A., Ha D., Schotte D., den Boer M.L., Armstrong S.A., Lodish H.F. A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells. Cell Cycle 2010, 9(6):1037-1042.
14. Liu L., Chen R., Huang S., Wu Y., Li G., Zhang B., et al. miR-153 sensitized the K562 cells to As2O3-induced apoptosis. Med Oncol 2012, 29(1):243-247.
15. Li Y., Zhu X., Gu J., Hu H., Dong D., Yao J., et al. Anti-miR-21 oligonucleotide enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by inducing apoptosis. Hematology 2010, 15(4):215-221.
16. Han B.W., Feng D.D., Li Z.G., Luo X.Q., Zhang H., Li X.J., et al. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum Mol Genet 2011, 20(24):4903-4915.
17. Bousquet M., Harris M.H., Zhou B., Lodish H.F. MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci U S A 2010, 107(50):21558-21563.
18. Klusmann J.H., Li Z., Bohmer K., Maroz A., Koch M.L., Emmrich S., et al. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev 2010, 24(5):478-490.
19. Ooi A.G., Sahoo D., Adorno M., Wang Y., Weissman I.L., Park C.Y. MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets. Proc Natl Acad Sci U S A 2010, 107(50):21505-21510.
20. Shaham L., Binder V., Gefen N., Borkhardt A., Izraeli S. MiR-125 in normal and malignant hematopoiesis. Leukemia 2012, 26(9):2011-2018.
21. O'Connell R.M., Chaudhuri A.A., Rao D.S., Gibson W.S., Balazs A.B., Baltimore D. MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci U S A 2010, 107(32):14235-14240.
22. Enomoto Y., Kitaura J., Hatakeyama K., Watanuki J., Akasaka T., Kato N., et al. Emu/miR-125b transgenic mice develop lethal B-cell malignancies. Leukemia 2011, 25(12):1849-1856.
23. Le M.T., Shyh-Chang N., Khaw S.L., Chin L., Teh C., Tay J., et al. Conserved regulation of p53 network dosage by microRNA-125b occurs through evolving miRNA-target gene pairs. PLoS Genet 2011, 7(9):e1002242.
24. Kong F., Sun C., Wang Z., Han L., Weng D., Lu Y., et al. miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. J Huazhong Univ Sci Technolog Med Sci 2011, 31(4):543-549.
25. Zhou M., Liu Z., Zhao Y., Ding Y., Liu H., Xi Y., et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010, 285(28):21496-21507.
26. Gefen N., Binder V., Zaliova M., Linka Y., Morrow M., Novosel A., et al. Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Leukemia 2010, 24(1):89-96.
27. Zhang H., Luo X.Q., Feng D.D., Zhang X.J., Wu J., Zheng Y.S., et al. Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer 2011, 10:108.
28. Schotte D., Akbari Moqadam F., Lange-Turenhout E.A., Chen C., van Ijcken W.F., Pieters R. Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia. Leukemia 2011, 25(9):1389-1399.
29. Wu S., Huang S., Ding J., Zhao Y., Liang L., Liu T., et al. Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region. Oncogene 2010, 29(15):2302-2308.
30. Beckman J.D., Chen C., Nguyen J., Thayanithy V., Subramanian S., Steer C.J., et al. Regulation of heme oxygenase-1 protein expression by miR-377 in combination with miR-217. J Biol Chem 2011, 286(5):3194-3202.
31. Efklidou S., Bailey R., Field N., Noursadeghi M., Collins M.K. vFLIP from KSHV inhibits anoikis of primary endothelial cells. J Cell Sci 2008, 121(Pt 4):450-457.
32. Bousquet M., Quelen C., Rosati R., Mansat-De Mas V., La Starza R., Bastard C. Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med 2008, 205(11):2499-2506.
33. Shi L., Zhang S., Feng K., Wu F., Wan Y., Wang Z., et al. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol 2012, 40(1):119-129.
34. Song T., Xia W., Shao N., Zhang X., Wang C., Wu Y., et al. Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev 2010, 11(4):905-911.
35. Nam E.J., Yoon H., Kim S.W., Kim H., Kim Y.T., Kim J.H., et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008, 14(9):2690-2695.
36. Ramakers-van Woerden N.L., Pieters R., Loonen A.H., Hubeek I., van Drunen E., Beverloo H.B. TEL/AML1 gene fusion is related to in vitro drug sensitivity for l-asparaginase in childhood acute lymphoblastic leukemia. Blood 2000, 96(3):1094-1099.
37. Holleman A., Cheok M.H., den Boer M.L., Yang W., Veerman A.J., Kazemier K.M. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004, 351(6):533-542.
38. Li Y., Vecchiarelli-Federico L.M., Li Y.J., Egan S.E., Spaner D., Hough M.R., et al. The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice. Blood 2012, 119(19):4486-4498. [Research Support, Non-U.S. Gov't].
39. Lee Y., Samaco R.C., Gatchel J.R., Thaller C., Orr H.T., Zoghbi H.Y. miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis. Nat Neurosci 2008, 11(10):1137-1139.
40. Doxakis E. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J Biol Chem 2010, 285(17):12726-12734.